Seeking Alpha

More on Actavis' (ACT) Q2: Revenue growth by segment: Actavis Pharma, +58%; Specialty Brands,...

More on Actavis' (ACT) Q2: Revenue growth by segment: Actavis Pharma, +58%; Specialty Brands, +21%; Distribution, +14%. FY13 outlook: EPS of $8.15-8.50 on sales of ~$8.1B (Pharma, $6.3-6.5B; Specialty Brands, $550-600M; Distribution, $1-1.2B). Consensus is $8.32/ share on revenue of $8.04B. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)